Sponsor or institution

Clinical trials and research at Genfleet Therapeutics (Shanghai) Inc.

• 8Clinical trials
• 2Countries

Newest trials

All recruiting trials (8)

• GFH375 plus GFH276 or GFH202A vs GFH375 alone in KRAS G12D pancreatic cancer

  This phase 2 study tests whether adding GFH276 or GFH202A to GFH375 helps people with KRAS G12D pancreatic cancer who have already had treatment.

  Recruiting Phase 2 Genfleet Therapeutics (Shanghai) Inc. · Shanghai, Shanghai Municipality · NCT07784374

• GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC

  This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.

  Recruiting at 10 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Concord, New South Wales and 16 other locations · NCT07678593

• GFH375 vs. Docetaxel for KRAS G12D-mutant NSCLC

  This study tests whether GFH375 can help people with KRAS G12D-mutant NSCLC more than docetaxel.

  Recruiting Phase 3 Genfleet Therapeutics (Shanghai) Inc. · Shanghai, Shanghai Municipality · NCT07668752

• GFH375 plus chemotherapy in KRAS G12D-mutant metastatic pancreatic cancer

  This trial tests GFH375 in combination with standard chemotherapy to see if it helps people with KRAS G12D-mutant metastatic pancreatic cancer who have already been treated fail or progress on prior therapy.

  Recruiting Phase 3 Genfleet Therapeutics (Shanghai) Inc. · Beijing, Beijing Municipality · NCT07262567

• GFH375 combined with cetuximab or chemotherapy for KRAS G12D–mutant solid tumors

  This tests whether adding GFH375 to cetuximab or to standard chemotherapy helps people with advanced solid tumors that have a KRAS G12D mutation.

  Recruiting Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Beijing, Beijing Municipality and 3 other locations · NCT07259590

• GFS202A for adults with advanced solid tumors and cachexia

  This study will test whether GFS202A is safe and tolerable in adults with advanced solid tumors who have pre-cachexia or cachexia.

  Recruiting Phase 1 Genfleet Therapeutics (Shanghai) Inc. · Guangzhou, Guangdong · NCT06898255

• Testing GFH375 in patients with advanced solid tumors that have KRAS G12D mutations

  This study is testing a new drug called GFH375 to see if it can help people with advanced solid tumors that have a specific KRAS G12D mutation.

  Recruiting at 13 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Hefei, Anhui and 19 other locations · NCT06500676

• GFH009 combined with Zanubrutinib for treating relapsed DLBCL

  This study is testing if a new treatment combining GFH009 and Zanubrutinib can help people with relapsed or hard-to-treat diffuse large B-cell lymphoma feel better.

  Recruiting at 2 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Nanning and 1 other locations · NCT06375733

Quick answers

How many clinical trials run by Genfleet Therapeutics (Shanghai) Inc. are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (8 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 4, Phase 3: 2, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →